Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathol. 2018;50:74–87.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortiu. Leukemia. 2012;26:2103–2113.
   PubMed Web of Science ®Google Scholar
• Younes A, Zinzani PL, Sehn LH, et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse larg. J Clin Oncol. 2014;32:TPS8615–TPS8615.
   Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649–662.
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of Ibrutinib and Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285–1295.
   PubMed Web of Science ®Google Scholar
• Burnet M. Cancer--A biological approach: I. The processes of control. II. The significance of somatic mutation. Br Med J. 1957;1:779–786.
   PubMed Web of Science ®Google Scholar
• Alimonti J, Zhang QJ, Gabathuler R, et al. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol. 2000;18:515–520.
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111.
   PubMed Web of Science ®Google Scholar
• Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12:93.
   PubMed Web of Science ®Google Scholar
• Santambrogio L, Berendam SJ, Engelhard VH. The antigen processing and presentation machinery in lymphatic endothelial cells. Front Immunol. [Internet]. 2019;10:1033. Available from.;:. : https://pubmed.ncbi.nlm.nih.gov/31134089
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol. 2001;1:126–134.
   PubMed Web of Science ®Google Scholar
• Leone P, Shin E-C, Perosa F, et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105:1172–1187.
   PubMedGoogle Scholar
• Khodadoust MS, Olsson N, Chen B, et al. B-cell lymphomas present immunoglobulin neoantigens. Blood J Am Soc Hematol..2019;133(8):878–881.
   Google Scholar
• Poggi A, Massaro A-M, Negrini S, et al. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol. 2005;174:2653–2660.
   PubMed Web of Science ®Google Scholar
• Langers I, Renoux VM, Thiry M, et al. Natural killer cells: role in local tumor growth and metastasis. Biologics. 2012;6:73–82.
   PubMedGoogle Scholar
• Lanier LL. Missing self, NK cells, and the white album. J Immunol. 2005;174:6565.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Disis ML. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest. 2004;113:664–667.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Cheah CY, Gascoyne RD, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101:531–540.
   PubMed Web of Science ®Google Scholar
• Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517–534.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunol. 2007;121:1–14.
   PubMed Web of Science ®Google Scholar
• Romero I, Garrido C, Algarra I, et al. T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res. 2014;74(7):1958–1968. .
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–S198. .
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007. DOI:10.1172/JCI31405
   PubMed Web of Science ®Google Scholar
• Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget. 2017;8:7175–7180.
   PubMedGoogle Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830–837.
   PubMed Web of Science ®Google Scholar
• Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22.
   Web of Science ®Google Scholar
• Mareschal S, Dubois S, Viailly P-J, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2016;55:251–267.
   PubMed Web of Science ®Google Scholar
• Greenawalt DM, Liang WS, Saif S, et al. Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum. Oncotarget. 2017;8:99237–99244.
   PubMedGoogle Scholar
• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.
   PubMed Web of Science ®Google Scholar
• Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–494.e15.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–1407.
   PubMed Web of Science ®Google Scholar
• Arthur SE, Jiang A, Grande BM, et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. Nat Commun. 2018;9:4001.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–690.
   PubMed Web of Science ®Google Scholar
• Karube K, Enjuanes A, Dlouhy I, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675–684.
   PubMed Web of Science ®Google Scholar
• Miao Y, Medeiros LJ, Li Y, et al. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019. DOI:10.1038/s41571-019-0225-1.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
   PubMed Web of Science ®Google Scholar
• Melchardt T, Hufnagl C, Weinstock DM, et al. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget. 2016. DOI:10.18632/oncotarget.9860.
   PubMedGoogle Scholar
• Jiang Y, Redmond D, Nie K, et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 2014;15:432.
   PubMed Web of Science ®Google Scholar
• de Miranda NFCC, Georgiou K, Chen L, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014;124:2544–2553.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.
   PubMed Web of Science ®Google Scholar
• Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? Oncoimmunol. 2017;6:e1295202–e1295202.
   PubMed Web of Science ®Google Scholar
• Neisig A, Melief CJ, Neefjes J, et al. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol. 1998;160:171–179.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109:3879–3884.
   PubMed Web of Science ®Google Scholar
• Kishore A, Petrek M. Next-generation sequencing based HLA typing: deciphering immunogenetic aspects of sarcoidosis. Front Genet. 2018;9:503.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–1271.e11.
   PubMed Web of Science ®Google Scholar
• Koller BH, Marrack P, Kappler JW, et al. Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science. 1990;248:1227–1230.
   PubMed Web of Science ®Google Scholar
• Jefferies WA, Kolaitis G, Gabathuler R. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides. J Immunol. 1993;151:2974 LP– 2985.
   Web of Science ®Google Scholar
• Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011;20::728–740.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Mareschal S, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22:2919–2928.
   PubMed Web of Science ®Google Scholar
• Bohers E, Viailly PJ, Dubois S, et al. Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica. 2015;100:e280–e284.
   PubMed Web of Science ®Google Scholar
• Sanchez-Madrid F, Krensky AM, Ware CF, et al. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci USA. 1982;79:7489–7493.
   PubMed Web of Science ®Google Scholar
• Bolhuis RL, Roozemond RC, van de Griend RJ. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J Immunol. 1986;136:3939–3944.
   PubMed Web of Science ®Google Scholar
• Leitner J, Herndler-Brandstetter D, Zlabinger GJ, et al. CD58/CD2 is the primary costimulatory pathway in human CD28 − CD8 + T cells. J Immunol. 2015;195:477–487.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mungall K, Pleasance E, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013;122. DOI:10.1182/blood-2013-02-483727.
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhu T, Zhang P, et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget. 2016;7:83294–83307.
   PubMedGoogle Scholar
• Ogryzko VV, Schiltz RL, Russanova V, et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87:953–959.
   PubMed Web of Science ®Google Scholar
• Kurokawa R, Kalafus D, Ogliastro MH, et al. Differential use of CREB binding protein-coactivator complexes. Science. 1998;279:700–703.
   PubMed Web of Science ®Google Scholar
• Duan W. Progress of next generation sequencing in activated B-cell like diffuse large B-cell lymphoma. J Leuk Lymphoma. 2017;26:249–251.
   Google Scholar
• Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–195.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ortega-Molina A, Geng H, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7:38–53.
   PubMed Web of Science ®Google Scholar
• Hashwah H, Schmid CA, Kasser S, et al. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc Natl Acad Sci USA. 2017;114:9701–9706.
   PubMed Web of Science ®Google Scholar
• Mondello P, Tadros S, Teater M, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. bioRxiv. 2019;531954.
   Google Scholar
• Zhang J, Vlasevska S, Wells VA, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 2017;7:322–337.
   PubMed Web of Science ®Google Scholar
• Sauer M, Schuldner M, Hoffmann N, et al. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene. 2017;36:933–941.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947–1957. .
   PubMed Web of Science ®Google Scholar
• Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22:2290–2300.
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Joffe E, Batlevi CL, et al. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J. 2018;8:60.
   PubMed Web of Science ®Google Scholar
• Juskevicius D, Jucker D, Klingbiel D, et al. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. J Hematol Oncol. 2017;10:70.
   PubMed Web of Science ®Google Scholar
• Devaiah BN, Singer DS. CIITA and its dual roles in MHC gene transcription. Front Immunol. 2013;37:476.
   Google Scholar
• Cycon KA, Rimsza LM, Murphy SP. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Exp Hematol. 2009;37:184–194.
   PubMed Web of Science ®Google Scholar
• Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13:1418–1431.
   PubMed Web of Science ®Google Scholar
• Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377–381.
   PubMed Web of Science ®Google Scholar
• Khodabakhshi AH, Morin RD, Fejes AP, et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012;3:1308–1319.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol. 2015. DOI:10.1053/j.seminhematol.2015.01.005
   PubMed Web of Science ®Google Scholar
• Hintzen RQ, Lens SM, Koopman G, et al. CD70 represents the human ligand for CD27. Int Immunol. 1994;6:477–480.
   PubMed Web of Science ®Google Scholar
• Bowman MR, Crimmins MA, Yetz-Aldape J, et al. The cloning of CD70 and its identification as the ligand for CD27. J Immunol. 1994;152:1756–1761.
   PubMed Web of Science ®Google Scholar
• Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood. 1995;85:3556–3565.
   PubMed Web of Science ®Google Scholar
• Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17:275–281.
   PubMed Web of Science ®Google Scholar
• Menter T, Tzankov A. Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol. 2018;8:54.
   PubMed Web of Science ®Google Scholar
• Yamada S, Shinozaki K, Agematsu K. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity. Clin Exp Immunol. 2002;130:424–430.
   PubMed Web of Science ®Google Scholar
• Park HY, Lee S-B, Yoo H-Y, et al. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma. Oncotarget. 2016;7:86433–86445.
   PubMedGoogle Scholar
• Afshar-Sterle S, Zotos D, Bernard NJ, et al. Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med. 2014;20:283–290.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Tsurumi H, Goto N, et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol. 2006;76:465–472.
   PubMed Web of Science ®Google Scholar
• Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30:180–192.
   PubMed Web of Science ®Google Scholar
• Muschen M, Rajewsky K, Kronke M, et al. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 2002;23:75–80.
   PubMed Web of Science ®Google Scholar
• Chatzitolios A, Venizelos I, Tripsiannis G, et al. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma. Ann Hematol. 2010;89:889–896.
   PubMed Web of Science ®Google Scholar
• Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 1997;272:14272–14276.
   PubMed Web of Science ®Google Scholar
• Cheung K-J-J, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010;70:9166–9174.
   PubMed Web of Science ®Google Scholar
• Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell. 2016;167:405–418.e13.
   PubMed Web of Science ®Google Scholar
• Menter T, Juskevicius D, Alikian M, et al. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017;178:48–56.
   PubMed Web of Science ®Google Scholar
• Lisiecka U, Kostro K. Mechanisms of tumour escape from immune surveillance. J Vet Res. 2016;60:453–460.
   Web of Science ®Google Scholar
• de Charette M, Houot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica. 2018;103:1256–1268.
   PubMed Web of Science ®Google Scholar
• Juskevicius D, Dirnhofer S, Tzankov A. Genetic background and evolution of relapses in aggressive B-cell lymphomas. Haematologica. 2017;102:1139–1149.
   PubMed Web of Science ®Google Scholar
• Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32:606–613.
   PubMed Web of Science ®Google Scholar
• Setiadi AF, Omilusik K, David MD, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008;68:9601–9607.
   PubMed Web of Science ®Google Scholar
• Setiadi AF, David MD, Seipp RP, et al. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol. 2007;27:7886–7894.
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity. Blood. 1998;92:3018–3024.
   PubMed Web of Science ®Google Scholar
• Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22:359–372.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z,. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32 (2018), pp. 1267–1284.
   PubMed Web of Science ®Google Scholar
• Urbach D, Lupien M, Karagas M.R, et al., Cancer heterogeneity: origins and implications for genetic association studies., Trends Genet. 28(11) (2012), pp. 538–543.
   PubMed Web of Science ®Google Scholar